OncLive SOSS

Authors

Ze'ev Ronai, PhD

Latest:

Dr Ronai on Key Advances in Melanoma Treatment Approaches

Ze'ev Ronai, PhD, discusses key advancements in the treatment of patients with melanoma, including the discovery of NRAS and BRAF mutations, as well as the development of immunotherapy approaches.

Kelly Garvin, MA, BSN, RN

Latest:

Garvin on the Benefits of CAR T-Cell Therapy in Non-Hodgkin Lymphoma

Kelly Garvin, MA, BSN, RN, discusses the impact of CAR T-cell therapy on the treatment of patients with non-Hodgkin lymphoma.

Lionel Kankeu Fonkoua, MD

Latest:

Dr Fonkoua on Addressing Barriers to Cancer Clinical Trial Access

Lionel A. Kankeu Fonkoua, MD, discusses the importance of addressing barriers to clinical trial access that patients with cancer may face and increasing patient access to routine, primary care.

Meghan Thompson, MD

Latest:

Dr. Thompson on the Rationale for the BRUIN Study in Richter Transformation

Meghan Thompson, MD, discusses the rationale for the phase 1/2 BRUIN study in patients with Richter transformation.

Latest:

ASCT Plus Isa-KRd Consolidation Does Not Boost MRD Negativity Rates in Myeloma

ASCT added to Isa-KRd consolidation following Isa-KRd induction did not improve MRD outcomes vs continued Isa-KRd in MRD-negative, newly diagnosed myeloma.

Eirwen M. Miller, MD

Latest:

Dr Miller on the Importance of Patient Advocacy in Gynecologic Oncology

Eirwen M. Miller, MD, discusses the importance of advocating for women in gynecologic oncology on International Women’s Day.

Latest:

Truong on the Rationale for Investigating ERK2 Substrate Binding Modalities in MPNs

Billy Truong discusses the rationale for investigating the functions of ERK2 substrate binding modalities in patients with myeloproliferative neoplasms.

Taliya Lantsman, MD

Taliya Lantsman, MD, is a hematology/oncology fellow at Beth Israel Deaconess Medical Center.

Latest:

Dr Lantsman on Future Directions for Evaluating Dostarlimab/Chemo in Endometrial Cancer

Taliya Lantsman, MD, discusses future research directions for assessing dostarlimab/chemotherapy in endometrial cancer in the real-world setting.

Reshma Mahtani, DO, Sylvester Comprehensive Cancer Center

Latest:

Using Systemic Therapy to Treat HER2+ Breast Cancer

Closing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.

Kathryn Gold, MD, UC San Diego Health

Latest:

Dr. Gold on Current Unmet Needs in Squamous Cell Carcinoma of the Lung

Kathryn A. Gold, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses current unmet needs in squamous cell carcinoma of the lung.

Toufic A. Kachaamy, MD

Toufic Kachaamy, MD, FASGE, AGAF, is an

Latest:

Leveraging Immunotherapy in GI Malignancies: Looking to the Future

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.

Kelly K. Hunt, MD, FACS, FSSO

Latest:

Dr. Hunt on Axillary Reverse Mapping in Breast Cancer

Kelly K. Hunt, MD, FACS, FSSO, discusses technical considerations for axillary reverse mapping in breast cancer for the reduction or prevention of lymphedema.

Elias K. Mai, MD

Latest:

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Dr. Elias K. Mai presents final progression-free survival results from the Phase 3 GMMG-HD7 trial, demonstrating that adding isatuximab to lenalidomide, bortezomib, and dexamethasone (Isa-RVd) significantly improves minimal residual disease negativity and reduces the risk of progression or death in transplant-eligible patients with newly diagnosed multiple myeloma.

Douglas Adkins, MD

Douglas Adkins, MD is a medical oncologist at the Siteman Cancer Center in Saint Louis, MO.

Latest:

Dr Adkins on the FDA Approval of Pembrolizumab for Neoadjuvant/Adjuvant Treatment in Resectable, Locally Advanced HNSCC

Douglas R. Adkins, MD, discusses the FDA approval of pembrolizumab for neoadjuvant and adjuvant treatment in resectable, locally advanced head and neck squamous cell carcinoma.

Alan J. Tackett, PhD

Latest:

Molecular Approaches May Increase Responsiveness to Immunotherapy for Patients With Metastatic Melanoma

The recent development of therapeutics which stimulate immune response to tumor cells has revolutionized the treatment landscape for cutaneous melanoma.

Gautam Jayram, MD

Latest:

Dr Jayram on the Role of Immunotherapy in Bladder Cancer

Gautam Jayram, MD, discusses the current indications for immunotherapy agents in the bladder cancer treatment paradigm, as well as immune-related adverse effects to be aware of when treating patients who are receiving these therapies.

Nicholas Stollenwerk, MD

Latest:

Dr. Stollenwerk on the Effect of Robotic Bronchoscopy on Lung Cancer Diagnosis

Nicholas Stollenwerk, MD, discusses the real-world effects of robotic-assisted bronchoscopy on diagnosis and treatment for patients with lung cancer.

Lori J. Wirth, MD, Massachusetts General Hospital

Latest:

Sequencing Throughout Multiple Lines of Therapy in RR DTC

Before closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.

Shannon L. Maude, MD, PhD

Latest:

Dr. Maude on Safety of Tisagenlecleucel in Pediatric B-ALL

Shannon L. Maude, MD, PhD, discusses notable long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.

Rami Manochakian, MD

x